Protocol Ledger

NCT05039515 · Phase II · TERMINATED

A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).

Interventional Phase II clinical trial protocol NCT05039515 sponsored by Clementia Pharmaceuticals in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-12-01 Enrollment: 113 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05039515
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)113 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05039515
Protocol FieldVerified Registry Value
NCT IdentifierNCT05039515
Consolidated Lead SponsorClementia Pharmaceuticals
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment113 participants (ACTUAL)
Registered Start Date2021-12-01
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI